MannKind Corporation (NASDAQ:MNKD), focused on discovering, developing and commercializing treatments for diabetes, announced that it will present at upcoming conferences.
Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, 2015 at 2:00 pm (ET) in New York, New York.
Goldman Sachs 36th Annual Global Healthcare Conference on Wednesday, June 10, 2015 at 8:40 am (PT) at the Terranea Resort in Rancho Palos Verdes, California.
JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 9:30 am (ET) at the St. Regis Hotel in New York, New York. (Original Source)
Shares of MannKind Corporation closed today at $5.27, up $0.45 or 9.34%. MNKD has a 1-year high of $11.48 and a 1-year low of $3.46. The stock’s 50-day moving average is $4.59 and its 200-day moving average is $5.55.
On the ratings front, MannKind has been the subject of a number of recent research reports. In a report issued on May 15, Jefferies Co. analyst Shaunak Deepak maintained a Buy rating on MNKD, with a price target of $9, which implies an upside of 701% from current levels. Separately, on May 11, J.P. Morgan’s Cory Kasimov downgraded the stock to Sell and has a price target of $6.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Shaunak Deepak and Cory Kasimov have a total average return of -13.0% and 12.7% respectively. Deepak has a success rate of 25.0% and is ranked #3172 out of 3607 analysts, while Kasimov has a success rate of 61.3% and is ranked #277.
Overall, one research analyst has rated the stock with a Sell rating, 2 research analysts have assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $4.75 which is -9.9% under where the stock opened today.
MannKind Corp is a development stage company engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes.